Curaleaf International today announced the launch of Curaleaf branded products in Australia.
The initial product offering, comprising four cannabis flower strains, will be distributed via Canngea, a licensed Australian manufacturer and wholesaler.
Over the coming months, patients and healthcare professionals in Australia can look forward to a broader portfolio offered by Curaleaf, including inhalation formats and popular strains.
"Entering the Australian market is a significant milestone in our global strategy to expand access to high-quality, evidence-backed cannabis medicines. We're committed to supporting Australian patients and healthcare professionals with reliable, consistent products and the backing of one of the industry's most advanced supply chains," said Juan Martinez, head of Curaleaf International.
"Australia is an exciting and rapidly evolving market, expected to surpass $1 billion in annual sales next year, and this launch is a positive step forward in our strategy to extend our position as the global leader in cannabis. We're bringing a proven portfolio and a strong track record of innovation, with more to come," said CEO Boris Jordan.
